Filing Overview
Phathom Pharmaceuticals, Inc. filed a Form 8-K dated January 9, 2023, under Item 8.01, to report topline results from the Phase 3 PHALCON-NERD-301 trial of investigational vonoprazan for symptomatic non-erosive gastroesophageal reflux disease (sGERD or NERD).
Key Trial Results
- The four-week, double-blind, placebo-controlled U.S. trial enrolled 776 patients.
- Both vonoprazan doses met the primary endpoint, demonstrating significantly more 24-hour heartburn-free days than placebo.
- Mean heartburn-free days were 46.4% for vonoprazan 10 mg, 46.0% for vonoprazan 20 mg, and 27.5% for placebo; both comparisons versus placebo had p<0.0001.
- Median heartburn-free days were 48.3%, 46.7%, and 17.0% for vonoprazan 10 mg, vonoprazan 20 mg, and placebo, respectively.
- Vonoprazan was generally well tolerated, with overall adverse events comparable to placebo. Nausea was the most common reported event: 2.3% for 10 mg, 3.1% for 20 mg, and 0.4% for placebo. No other event exceeded 3.0% in either vonoprazan arm.
Business Context and Outlook
Vonoprazan is an investigational potassium-competitive acid blocker intended to inhibit stomach acid secretion. The trial includes an ongoing blinded 20-week extension to evaluate safety and efficacy after six months of continuous use. Full study results were expected later in 2023.
Phathom was in discussions with the FDA regarding a separate Phase 3 trial evaluating vonoprazan as an on-demand treatment for episodic heartburn in patients with NERD. The company indicated that NERD-301 data could support a future FDA marketing application, but no application approval or submission was reported in this filing.
Financial Position and Other Metrics
This Item 8.01 filing does not provide revenue, profit or loss, cash flow, margin, debt, liquidity, or other corporate financial metrics. The filing states that access to additional capital under the company’s term loan facility and royalty interest financing agreements is subject to specified conditions.
Material Changes, Risks, and Contingencies
- The reported topline data were based on preliminary analyses and remained subject to trial completion, audit, and verification, which could materially change the final results.
- The FDA could determine that existing safety and efficacy data are insufficient for an NDA submission for symptomatic NERD, or FDA actions concerning the company’s other programs could delay or negatively affect the NERD program.
- Key risks include clinical-development uncertainty, unexpected adverse effects or inadequate efficacy, regulatory developments, manufacturing and supply-chain dependence on third parties, intellectual-property protection, compliance with the Takeda license agreement, financing conditions, and potential clinical-trial or operational disruption.
Investor Verification Points
- Verify the final audited and complete NERD-301 results, including whether topline efficacy and safety findings changed.
- Review results from the 20-week extension and any subsequent FDA feedback or NDA submission.
- Confirm the design, timing, and outcome of any Phase 3 on-demand dosing trial.
- Assess the company’s latest cash resources, debt and royalty-financing terms, and conditions for accessing additional capital, which are not provided in this filing.
- Review the company’s subsequent SEC filings for regulatory, safety, manufacturing, financing, and commercialization developments.